Karin Schölin Bywall

Karin Schölin Bywall
MSc Public Health
PhD Student
Karin Schölin Bywall is a PhD student in the IMI-funded PREFER project. The project is aiming to investigate methodologies to elicit informed patient preferences regarding the benefits and risks of drugs, from development through the entire cycle, to inform the decision-making process by regulators and HTA bodies.
Karin Schölin Bywall has a master of science in public health from Mälardalen University where she also teached in public health.
E-mail: karin.bywall@crb.uu.se
Phone: +46 18 471 62 49
Recently in the media
- Patienters syn på att inkluderas i forskning om läkemedel
Reumatikerförbundet, 2018-12-18 - Study explores patient preferences in second-line RA treatment
AJMC, 2021-01-23
Publications
-
Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients
Part of Arthritis Research & Therapy, 2020.
-
An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?
Part of Health Policy, p. 1325-1332, 2020.
-
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study
Part of Frontiers in Pharmacology, 2019.
-
Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US
Part of Frontiers in Pharmacology, 2019.
-
Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA
Part of Patient, p. 513-526, 2019.
-
Patient Perspectives on the Value of Patient Preference Information in Regulatory Decision Making: A Qualitative Study in Swedish Patients with Rheumatoid Arthritis
Part of Patient, p. 297-305, 2019.
Risk information

We are investigating risk information from serval perspectives.
Patient preferences
Giving patients a voice in drug development

PREFER is a five year public-private research project where academic researchers and the pharmaceutical industry work together to find out when and where patients want, can and should be involved in drug development
Patient prefrences
Rheumatoid Arthritis

Karin Schölin Bywall will look at how rheumatoid arthritis patient preferences can provide added value in regulatory decision making in the drug development process.
Methodology, rheumatoid arthritis and patient involvement
Drugs should benefit patients. By extension, they should have a say in designing research meant to find out what they think about drugs. Here, Karin Schölin Bywall shares her thoughts about involving patients in research and working together with stakeholders.
